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ABSTRACT 
Neuroblastoma and medulloblastoma are embryonal malignant tumors of the central and 
peripheral nervous systems, respectively. The overall survival for both diagnoses is 60-75% 
despite intense multimodal therapy. This warrants the search for novel therapeutic 
approaches. Hedgehog (HH) and Wingless (WNT) signaling pathways are important 
regulators of embryogenesis that have been associated with the development of cancer 
including medulloblastoma. HH signaling is characterized by Smoothened (SMO)-dependent 
activation of the GLI transcription factors. WNT signaling is divided into canonical and non-
canonical signaling. Canonical signaling involves the key molecule β-catenin while non-
canonical signaling includes the planar cell polarity pathway (PCP). PCP signaling including 
the Rac/Rho cascade are important for proper migration and differentiation of neural crest 
cells during neuritogenesis. In this thesis we have assessed the role of HH and WNT 
signaling in neuroblastoma and medulloblastoma, with the aim to gain insights and develop 
novel therapeutic approaches based on biological understanding of the diseases. 
Key molecules within the HH signaling pathway are overexpressed in neuroblastoma. We 
investigated the effects of inhibiting HH signaling in neuroblastoma and found that inhibition 
of GLI was more effective in reducing neuroblastoma growth compared to inhibition of SMO 
located more upstream in the signaling pathway. The GLI inhibitor GANT61 effectively 
repressed neuroblastoma growth in vitro and in vivo, downregulated c-MYC, GLI1, MYCN 
and Cyclin D1 expression and augmented the cytotoxic effects when combined with 
clinically used chemotherapeutic drugs. These findings suggest that inhibition of HH 
signaling is a highly relevant therapeutic target for high-risk neuroblastoma (Paper I). The 
DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) is frequently 
overexpressed in cancers and is coupled to chemoresistance. In a search for new inhibitors for 
MGMT we investigated cellular regulators of MGMT expression in multiple cancers 
including neuroblastoma and medulloblastoma. We found a significant correlation between 
WNT signaling and MGMT expression that was confirmed by bioinformatic analysis and 
studies of protein expression of MGMT and β-catenin. Pharmacological as well as genetic 
inhibition of WNT activity downregulated the MGMT expression and restored 
chemosensitivity of the DNA-alkylating drug temozolomide in vitro and in vivo. These 
results have possible therapeutic entailments for chemoresistant cancers, especially of brain 
tumors where temozolomide is commonly used in treatment (Paper II).  
Investigating non-canonical WNT signaling in neuroblastoma revealed that overexpression of 
PCP core genes Prickle1 and Vangl2 led to suppression of neuroblastoma cell growth and 
reduced Wnt/β-catenin signaling. On the other hand, overexpression of Vangl2 in neural stem 
cells produced accumulation of active β-catenin and decreased differentiation, suggesting 
different roles of PCP proteins in tumorigenic cells compared to normal cells (Paper III). 
Furthermore, genetic analyses demonstrated that neuroblastoma tumors harbor frequent 
mutations of genes controlling neuritogenesis associated with the Rac/Rho signaling cascade. 
The majority of these mutations were described to result in inhibition of Rac or activation of 
Rho. Inhibition of ROCK, a key enzyme downstream of Rho, resulted in differentiation, 
inhibition of neuroblastoma cell growth and migration and degradation of MYCN protein. 
Small molecule inhibition of ROCK suppressed MYCN-driven neuroblastoma growth both in 
a transgenic and in a xenograft model. This study proposes that manipulation of Rho 
signaling might offer new therapeutic alternatives for neuroblastoma (Paper IV).  
Taken together, the work in this thesis demonstrates that the embryonal signaling pathways 
HH and WNT may offer new therapeutic targets for neuroblastoma and medulloblastoma.   
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1 INTRODUCTION 
1.1 CANCER 
Cancer is a term for diseases in which human cells become abnormal and start to divide 
without cessation. Cancer development involves several genomic changes, and the 
transformation of normal cells to cancer cells is a multistep process (Hanahan and Weinberg, 
2000). Every day new cells are generated in the human body through cell division. This 
process is precisely controlled by multiple molecular and cellular mechanisms. However, 
accidentally cells with acquired capacities to proliferate, migrate and invade other parts of the 
body develop, that eventually result in malignant cancer (Hanahan and Weinberg, 2000). 
Defined by Hanahan and Weinberg, a cancer cell needs to have six biological capabilities to 
develop a human tumor or neoplasm. The six hallmarks are: sustaining proliferative signals, 
evading growth suppressors, activating invasion and metastasis, enabling replicative 
immortality, inducing angiogenesis and resisting cell death, essential for these hallmarks are 
inflammation, reprogrammed metabolism, evading immune destruction and genomic 
instability (Hanahan and Weinberg, 2011).   
Cancer is still one of the leading causes of death worldwide. Despite significant improvement 
in cancer therapeutics, cancer is estimated to be the major cause of mortality in the coming 
decades worldwide, irrespective of income level. The predicted global burden as of 2030 is 
estimated at 20.3 million new cancer cases, compared to 12.7 million cases 2008. The 
predicted survival rate in 2030 is estimated to be 65% (Bray et al., 2012).   
The development of new, more effective treatments is needed and it is necessary to find new 
potential targets of these diseases. My hope is that by increasing knowledge about signaling 
pathways aberrantly expressed in different tumors along with a better understanding of the 
mechanisms behind cancer development and progression, what will contribute to a higher 
cure rate for cancer patients in the future.   
Pediatric cancers are neoplasms that occur in children and represent <2% of human cancers. 
The incidence of childhood cancers diverges with age and sex and is the most common 
reason of death from non-communicable diseases in children >1 year. Embryonal tumors 
account for roughly 20% of cancers seen in children <15 years of age and the survival for 
children with these tumors have increased during the last 60 years (Gustafsson et al., 2013) 
(figure 1). The tumors consist of very undifferentiated cells similar to the cells in a 
developing embryo. Embryonic tumors include: medulloblastomas, primitive 
neuroectodermal tumors (PNETs), atypical teratoid/rhabdoid tumor (AT/RT), neuroblastoma, 
ganglioneuroblastoma, retinoblastoma, nephroblastoma and hepatoblastoma (Tulla et al., 
2015).  
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1.2 NEUROBLASTOMA 
1.2.1 Neuroblastoma biology 
Neuroblastoma is an embryonal childhood tumor that arises in the tissue of the adrenal 
medulla, paraspinal ganglia or sympathetic ganglia (Maris, 2010; Ora and Eggert, 2011; 
Schulte and Eggert, 2015). Neuroblastoma accounts for about 6% of all childhood cancers, 
but for 9% of all childhood cancer deaths (Gustafsson et al., 2013; Johnsen et al., 2009). It 
most frequently occurs in the adrenal medulla (Garner and Beierle, 2015) and the median age 
at diagnosis is 17-18 months (Brodeur, 2003; Maris, 2010). In Sweden, 10-20 children are 
diagnosed with neuroblastoma each year, with the mean annual incidence rate of 0.7 
cases/100 000 children <15 years of age (1984-2010) (Gustafsson et al., 2013).  
 
 
Figure 1. The estimated prognosis (5-years survival) over time for selected diagnostic groups. The 
prognosis improved considerably during time period 1970-1995. The results during the last decades appear to 
have reached a plateau, although neuroblastoma and CNS tumors seem to have a continued improved five-
year survival. Adapted from (Gustafsson et al., 2013), with permission from the publisher.  
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Neuroblastoma is an undifferentiated tumor, consisting of small, round blue cells. These cells 
are called neuroblasts and rarely differentiate spontaneously. However, some tumors show 
some differentiation and are called ganglioneuroblastomas. The furthermost differentiated 
form is called ganglioneuroma (Brodeur, 2003). 
Some neuroblastomas have the unique ability to regress spontaneously or differentiate into a 
benign ganglioneuroma. This spontaneous regression is particularly seen in infants. Older 
children more often have widespread or metastatic disease at the time of diagnosis and 
therefore an overall poorer prognosis (Brodeur, 2003). Neuroblastomas mostly metastasize to 
lymph nodes, bone and bone marrow (figure 2) (Johnsen et al., 2009). The tumor is believed 
to originate from primitive precursor cells present in the neural crest and is the most common 
and deadly extracranial solid tumor in children (Brodeur, 2003; Louis and Shohet, 2015; 
Ratner et al., 2016; Schulte and Eggert, 2015). The neural crest is a transient structure present 
during embryonal development and neural crest cells migrate during mid-gestation 
throughout the body along two defined routes, one ventral pathway giving rise to glial cells 
and neurons and one lateral pathway giving rise to melanocytes (Green et al., 2015; Mohlin et 
al., 2011; Takahashi et al., 2013). These migrating progenitor cells are extremely proliferative 
and are regulated through interplay between different signaling pathways (Green et al., 2015; 
Jacob, 2015; Newbern, 2015; Szabo and Mayor, 2016). Cells in the embryo are exposed and 
guided by different signaling factors and strong proliferative signals drive the growth of the 
embryo and limit the cells to differentiate and exit the cell cycle (Green et al., 2015; Maguire 
et al., 2015; Munoz and Trainor, 2015). Therefore, changes in the guiding signals and the 
inability of progenitor cells to differentiate and exit the proliferative state could promote 
transformation and potentially drive tumor formation and development of neuroblastoma 
(Grimmer and Weiss, 2006; Johnsen et al., 2009; Louis and Shohet, 2015; Maguire et al., 
2015).  
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1.2.2 Neuroblastoma genetics and prognostic factors 
Neuroblastoma shows heterogeneous biological and clinical features extending from natural 
regression to extremely malignant disease with metastatic spread (Brodeur, 2003). 
Spontaneous regression was described as early as 1927 in a paper by Cushing and Wohlbach 
(Cushing and Wolbach, 1927). The prognosis for the patient prominently depends on two 
factors: the age of the patient at diagnosis and whether the tumor has metastasized. Younger 
children tend to respond better to treatment, especially children with less widespread disease 
(Breslow and McCann, 1971). Aside from age and tumor burden, there are some genetic, 
molecular and histological patterns that are of importance for the prognosis and can be useful 
in the choice of therapy.  
Somatic genetic changes, for example activation of oncogenes, gain or loss of alleles, or 
changes in tumor cell ploidy are of importance in the development of neuroblastoma 
(Brodeur, 2003). The v-myc avian myelocytomatosis viral oncogene neuroblastoma (MYCN) 
proto-oncogene located at the 2p24 locus is frequently amplified (22%) or overexpressed and 
several studies have revealed that it characterizes a subset of very aggressive neuroblastomas 
correlated with poor prognosis. MYCN is a transcription factor that forms heterodimers with 
the MAX protein, and this complex activates transcription of several target genes. These 
target genes are widely involved in metabolism, apoptosis and cell growth (Brodeur, 2003; 
Johnsen et al., 2009; Mohlin et al., 2011). In neuroblastoma MYCN can be amplified five to 
several hundred-fold and the amplification leads to increased proliferation, decreased 
apoptosis and may also cause a differentiation arrest (Lu et al., 2003; Schwab, 1993).  
Other genetic changes identified in neuroblastomas are complete or partial gain of 
chromosome 17q and deletions of the short arm of chromosome 1 (1p). The most frequent 
Figure 2. Illustration of neuroblastoma 
and potential locations. Neuroblastoma 
primary tumors derived from the neural crest 
arise in the sympathetic nervous system 
including the adrenal medulla, sympathetic 
ganglia and paraganglia. Neuroblastomas 
mainly metastasize to lymph nodes, bone 
and bone marrow, and in infants also spread 
to liver and subcutaneous tissue.  
Reprinted from (Johnsen et al., 2009) with 
permission of Springer. 
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genetic abnormality is gain of chromosome 17q, with an incidence rate of 63-83% (Caren et 
al., 2010). This gain is associated with an advanced disease and more often found in tumors 
of children older than one year (Caren et al., 2010). Some of the 17q gain tumors also show 
loss of 1p and amplification of MYCN (Abel et al., 1999; Bown et al., 1999). Loss of 
heterozygosity (LOH) on chromosome 11q is another genetic abnormality in neuroblastoma. 
The LOH is rarely coupled with MYCN amplification but despite MYCN amplification, the 
LOH on chromosome 11q is associated with an aggressive disease and decreased probability 
of survival (Attiyeh et al., 2005; Caren et al., 2010).  
About 1-2% of neuroblastomas are inherited in an autosomal dominant manner. The most 
commonly affected gene in these neuroblastomas is activating mutations of the anaplastic 
lymphoma kinase (ALK) oncogene (Mosse et al., 2008). Also, somatic mutations of the ALK 
gene have been found in 7-10% of neuroblastoma making this tyrosine kinase transmembrane 
receptor an attractive target for treatment for this group of neuroblastoma patients (Caren et 
al., 2008; Chen et al., 2008; George et al., 2008; Hallberg and Palmer, 2013; Janoueix-
Lerosey et al., 2008; Molenaar et al., 2012; Pugh et al., 2013).  
 
1.2.3 Neuroblastoma staging and treatment 
The clinical staging criteria are used as a measure of the tumor burden in the patient. All of 
the above should be taken into account when appropriate treatment is chosen for the patient. 
There have been different staging systems over the years. In 1988, a new revised 
neuroblastoma staging system known as the International Neuroblastoma Staging System 
(INSS) was presented. This was based on new research and a better understanding of the 
disease (Brodeur et al., 1993). However, later it was shown that this staging system had some 
weaknesses and treatments among different cooperative groups were not based on the same 
prognostically genetic features. Therefore, a new International Neuroblastoma Risk Group 
Staging System (INRGSS) was developed that will ensure that children, irrespective of 
nationality are stratified into identical treatment groups. This system was designed to stratify 
patients pre-treatment, together with prognostic factors including histology, MYCN status, 
age, 11q status, and DNA ploidy (Cohn et al., 2009). Locoregional tumors are staged as L1 or 
L2 based on the presence or absence of Image defined risk factors (IDRF). Metastatic spread 
tumors are staged as M, except when the metastases are restricted to liver, skin and/or bone 
marrow in children below 18 months of age. They are staged as MS (Monclair et al., 2009). 
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Stage Description 
L1 Localized tumor not involving vital structures as defined by the list of image-
defined risk factors and confined to one body compartment 
L2 Locoregional tumor with presence of one or more image-defined risk factors 
M Distant metastatic disease (except stage MS)  
MS Metastatic disease in children younger than 18 months with metastases confined to 
skin, liver, and/or bone marrow. 
Table 1. International Neuroblastoma Risk Group Staging System. Adapted from (Monclair et al., 2009), 
with permission from American Society of Clinical Oncology. 
 
The current treatment for children with neuroblastoma, stratified into the high-risk group, 
includes chemotherapy, surgical resection, myeloablation, local radiation and treatment with 
13-cis retinoic acid (Ora and Eggert, 2011; Pearson et al., 2008). The common European 
induction chemotherapy includes dose cycles of etoposide and cisplatin alternating with 
vincristine, doxorubicin and cyclophosphamide (Pearson et al., 2008). For tumors that are 
stratified into lower risk groups, the current trend has been to reduce the intensity of the 
therapy without myeloablation and avoiding radiotherapy and chemotherapy in many 
children (Maris, 2010; Ora and Eggert, 2011). 
 
1.3 MEDULLOBLASTOMA 
1.3.1 Medulloblastoma biology 
Brain tumors are the second most common cancer diagnosis in children below 15 years of 
age. Medulloblastoma is the most common malignant pediatric brain tumor. In Sweden, 10-
15 children are diagnosed with medulloblastomas every year with a peak incidence at seven 
years of age (Gustafsson et al., 2013; Lannering et al., 2009; Polkinghorn and Tarbell, 2007). 
The male/female ratio of medulloblastoma is 1.5:1 (Coluccia et al., 2016) and in Sweden, the 
overall survival rate is 58.8 % (Gustafsson et al., 2013). Symptoms of medulloblastoma 
include morning vomiting, headache and truncal ataxia, which usually exist for 1.5-3 months 
before diagnosis (Polkinghorn and Tarbell, 2007). The tumor most often arises in the 
cerebellum, and is believed to originate from primitive neuronal cells (Northcott et al., 2011). 
It has been shown by gene-array data, that medulloblastomas are molecularly different from 
other brain tumors including PNETs (figure 3) (Guessous et al., 2008; Pomeroy et al., 2002). 
There are two major germinal zones involved in the development of the cerebellum: the 
ventricular zone (VZ) and the external granule layer (EGL). The VZ gives rise to neurons and 
glia cells and is found at the top of the fourth ventricle. The EGL, on the other hand, gives 
rise to glutaminergic neurons and is found on the posterior external surface of the cerebellum 
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(Coluccia et al., 2016). Medulloblastoma is, according to the WHO, classified as a grade IV 
tumor and histopathologically classified into different subgroups: classic medulloblastomas 
(CMB), desmoplastic/nodular medulloblastomas (DMB), extensive nodularity (MBEN) and 
large cell/anaplastic (LC/AMB) (Guessous et al., 2008; Polkinghorn and Tarbell, 2007). The 
histological grading assists in predicting the biological behavior and is a key factor 
influencing the choice of tumor treatment (Louis et al., 2007).  
 
 
1.3.2 Molecular subgroups of Medulloblastoma 
The development and growth of medulloblastoma has been associated with several molecular 
dysfunctions. These molecular aberrations include deregulation of developmental signaling 
pathways, important for normal embryonal development, such as hedgehog (HH), wingless 
(WNT) and deregulation of other oncogenic pathways including c-MYC and MYCN 
(Guessous et al., 2008). In recent years, tremendous improvements have been made in 
understanding the biology and pathogenesis of medulloblastoma. Large-scale genetic, 
transcriptome and epigenetic analysis of medulloblastomas worldwide has revealed four 
different molecular subgroups. The four principal subgroups have been named: Sonic 
Hedgehog (SHH), WNT, group 3 and group 4 (Taylor et al., 2012) (figure 4). The four 
subgroups have different demographic parameters, tumor appearance and clinical behavior 
(Coluccia et al., 2016).  
Figure 3. Illustration of 
medulloblastomas localization. 
Medulloblastoma primary 
tumors arise in the infratentorial 
posterior fossa of the CNS 
whereas supratentorial primitive 
neuroectodermal tumours 
(sPNET) arise in the superior 
fossa (indicated by asterisk, *). 
Reprinted from (Johnsen et al., 
2009) with permission of 
Springer. 
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The SHH group is named after the Sonic Hedgehog signaling pathway. This signal 
transduction pathway is important for granule cell progenitor (GCP) proliferation and 
purkinje cells provide the signal by secreting the SHH glycoprotein. Aberrant development of 
granule cells can result in medulloblastomas and includes both excess and absence of signals 
for GCPs to proliferate (Polkinghorn and Tarbell, 2007). The SHH medulloblastomas are 
Figure 4. Features of the four medulloblastoma subgroups. Claudia C. Faria, Christian A. Smith and 
James T. Rutka (2013). New Molecular Targets and Treatments for Pediatric Brain Tumors, Evolution of the 
Molecular Biology of Brain Tumors and the Therapeutic Implications, Dr. Terry Lichtor (Ed.), InTech, DOI: 
10.5772/53300. Available from: http://www.intechopen.com/books/evolution-of-the-molecular-biology-of-
brain-tumors-and-the-therapeutic-implications/new-molecular-targets-and-treatments-for-pediatric-brain-
tumors. Reproduced with permission from the authors. 
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primarily found in infants (0-3 years) and adults (>16 years). Most of the 
nodular/desmoplastic medulloblastomas are classified into the SHH group (Taylor et al., 
2012). SHH tumors frequently express high levels of MYCN as well as loss off chromosome 
9q (Northcott et al., 2011). The prognoses for medulloblastoma patients with SHH tumors, 
are intermediate and similar to group 4 patients.  
Germline mutations in the receptor protein patched homologue 1 (PTCH1) that result in 
constitutive activation of the pathway cause a condition termed Gorlin syndrome (described 
on page 16). These individuals have a predisposition to develop medulloblastomas (Taylor et 
al., 2012). 
The WNT group is named after the WNT signal transduction pathway and arises from cells 
of the lower rhombic lip (Phoenix et al., 2016). This group has a very good prognosis 
compared to the other three subgroups and the long-term survival for patients in this group is 
>90%. The WNT pathway is important for cell proliferation and WNT medulloblastomas are 
commonly somatic mutated in CTNNB1 encoding β-catenin. These tumors also show 
chromosome 6 monosomy (Taylor et al., 2012). Tumors in the WNT subgroup are distributed 
across all age groups but are more common in older children. The tumors have a classic 
histopathology (Northcott et al., 2011). One new hypothesis for why WNT patients have an 
excellent survival rate is that WNT medulloblastomas secrete WNT antagonists that silence 
WNT signaling in neighboring endothelial cells. As a result, a formation of a highly aberrant 
and hemorrhagic vasculature occurs that lacks an intact blood brain barrier and therefore, 
these tumors are more susceptible to chemotherapy and more curable (Phoenix et al., 2016).  
Group 3 medulloblastomas are believed to arise from cerebellar progenitor cells (Kawauchi et 
al., 2012). The tumors usually express high levels of c-MYC and c-MYC gene amplification 
seems to be restricted to this group. Amplification and over expression of the OTX2 gene is 
also limited to group 3 and group 4 tumors. OTX2 is a transcription factor that plays an 
important role in brain morphogenesis and when dysregulated may be involved in neoplasmic 
transformation (Di et al., 2005). Some of the tumors in group 3 display gain of chromosome 
1q, or/and loss of chromosome 10q and 5q. Tumors in this group are seen in infants and 
children and more frequently observed in males than females. Many group 3 tumors belong 
to LC/AMB histology, and are commonly metastatic. This group has a poor prognosis 
(Taylor et al., 2012).  
Group 4 tumors are more similar to group 3 tumors than to SHH or WNT tumors and 66% of 
the tumors in this group have an isochromosome 17q change. Loss of chromosome X is also 
seen in this group. There are reports that show that 80% of females in group 4 have a loss of 
chromosome X. The male/female ratio in this group is 2:1, and most of the tumors belong to 
classic medulloblastomas histology (Taylor et al., 2012). The peak incidence is 5-13 years of 
age. Group 4 patients have an intermediate prognosis (Kool et al., 2012).  
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1.3.3 Therapy for Medulloblastoma 
Current treatment often includes surgery, radiation and chemotherapy. Even though the 
survival rates have increased during the last few years and the Nordic countries have a high 
cure rate compared to other international population studies, there are still improvements to 
be made (Lannering et al., 2009). The treatment depends upon age, metastatic status, 
subgroup classification and extent of surgical resection. Surgery is performed to collect 
tissue, reduce mass effect and recreate changed or obstructed cerebrospinal fluid. This is 
followed by radiotherapy. Radiotherapy is only given to children older than 3-5 years of age. 
This is due to the higher sensitivity for radiation correlated to cognitive impairments in 
children younger than 3 to 5 years (von Hoff and Rutkowski, 2012). Following radiotherapy, 
the children are treated with chemotherapy. The addition of chemotherapy after radiation has 
increased survival rates and allowed a decrease of radiotherapy doses, especially for standard 
risk patients. Commonly, a combination of either cisplatin, N-(2-chloroethyl)-N-cyclo-hexyl-
N-nitrosurea (CCNU) and vincristine are given for eight cycles or a combination of cisplatin, 
cyclophosphamide and vincristine (von Hoff and Rutkowski, 2012). Depending on the dose 
and volume of used radiotherapy and age at diagnosis, survivors often suffer from life-
altering side effects of treatment that increase over time. These life-altering side effects 
include neurological, endocrinological and social sequelae (Northcott et al., 2011). Because 
of this, it is important to investigate candidates for targeted therapy with fewer side effects 
with the potential to directly target underlying abnormal signaling pathways included in the 
different molecular subgroups (von Hoff and Rutkowski, 2012).  
 
1.3.4 Resistance to therapy 
Despite progress in improving survival over the past decades, there is still a reduced quality 
of life for survivors and some patients will still relapse and have a negative prognosis 
(Gottardo et al., 2014). These relapses can occur many years after the diagnosis of the 
primary tumor. Development of resistance to chemotherapeutic drugs is another major 
problem. There is increasing interest in the possibility that resistance to chemotherapeutic 
drugs is caused by cancer stem cells (CSC). Therefore, stem cell specific pathways may 
provide desirable targets to sensitize CSC to therapy. Experiments have shown that the most 
aggressive medulloblastomas have a high proportion of cells expressing CD133. CD133 itself 
seems to be a marker of both normal neural stem cells and CSC. Moreover, cells expressing 
CD133 preferentially activate DNA repair proteins more effectively than CD133-negative 
cells. Ultimately this population of cells have evolved a more effective system for repairing 
DNA damage, causing them to become resistant to radiation treatment (Visvader and 
Lindeman, 2008).  
One enzyme that repairs DNA damage is O6-Methylguanine-DNA methyltransferase 
(MGMT). MGMT is the main enzyme in the defense against mutation-driven carcinogenesis 
caused by O6 alkylators. Alkylating agents are extremely reactive molecules that cause cell 
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death by binding to DNA and are used in the therapy of many different types of cancer, for 
example brain tumors as medulloblastoma. There can be many alkylation lesions initiated in 
the DNA, but the most mutagenic is on the O6 position of the DNA base guanine. MGMT 
repairs these O6MeG by transferring the alkyl group to a cysteine residue. After the transfer, 
the MGMT protein becomes inactivated and marked for degradation. As a result of this, the 
amount of lesions that can be repaired are equal to the amount of MGMT (Christmann et al., 
2011). The promoter that controls the expression and activity of MGMT can be methylated. 
The methylation of the promoter silences the gene and the cells stop producing MGMT. 
Patients with lower expression of MGMT have been shown to have a better overall and 
disease-free survival and respond better to alkylating agents than patients with high MGMT 
levels (Esteller et al., 2000). Furthermore, it is of great interest to increase the sensitivity to 
alkylators in resistant tumors, by inhibiting the MGMT enzyme. There are several MGMT 
inhibitors on the market that have been shown to inactivate MGMT activity but still, this 
depletion also depresses basal levels of MGMT in normal cells leading to myelosuppression 
(Esteller et al., 2000).  
 
2 DEVELOPMENTAL WNT AND HH SIGNALING IN 
CANCER  
2.1 WNT SIGNALING 
Cell signaling is a key factor in the development of all multicellular organisms. WNTs are 
secreted lipid-modified signaling proteins that seem to predominantly function over short 
distances and are important for normal development of the embryo (Clevers et al., 2014). The 
WNTs form a large family consisting of 19 WNT proteins, which share 27% to 83% 
similarity in the amino acid sequences (Miller, 2002). The first WNT gene, Wnt-1, was 
discovered in 1982 and was found to be a proto-oncogene that causes mammary tumors in 
mice (Nusse and Varmus, 1982). WNTs are involved in many cellular activities and influence 
multiple processes during development, including differentiation, proliferation, survival, 
movement and polarity. Several reports show that inappropriate WNT activity is linked to 
developmental defects and to a variety of cancer, including medulloblastomas and 
neuroblastomas (Gibson et al., 2010; Liu et al., 2008; Miller, 2002; Northcott et al., 2012; 
Northcott et al., 2011).  
Transduction and response of WNT signals involves binding of WNT proteins to two 
different classes of cell surface receptors, the Frizzled (Fz) receptors and the LDL-receptor 
related protein (LRP) (Bejsovec, 2000). There are ten different known types of Fz receptors 
in humans, which bind different WNTs with varying specificity (Miller, 2002). The 
mechanism of LRP signaling is uncertain but the suggestion is a binding between the 
cytoplasmic domain of LRP and the WNT antagonist Axin (Mao et al., 2001). After binding 
to the receptors, the WNT signals are transduced through at least three different intracellular 
signaling pathways. The most studied pathway is referred to as the canonical WNT/β-catenin 
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pathway. The two other pathways are both denoted non-canonical pathways. They are 
divided into the WNT/planar cell polarity (PCP) pathway and the WNT/Ca2+ pathway. 
Dependent of the combination of WNTs and Fz, one of these pathways is activated and this 
will lead to unique cellular responses (Miller, 2002).  
 
2.1.1 Canonical WNT signaling 
The central player in this pathway is β-catenin. In the absence of a WNT ligand, the level of 
β-catenin is kept low. This is done by continually targeting β-catenin for ubiquitination and 
degradation in the proteasome by phosphorylation through glycogen synthase-3β (GSK-3β) 
and casein kinase 1 (CK1) attached to a scaffolding complex consisting of adenomatous 
polyposis coli (APC) and Axin. This complex of proteins is called the destruction box 
(Nelson and Nusse, 2004). The free levels of β-catenin remain subsequently low, which lets 
the DNA binding T-cell factor/lymphoid enhancer factor (Tcf/Lef) proteins to bind to 
transcriptional co-repressors, such as Groucho and block the transcription of target genes 
(Barker and Clevers, 2006; Clevers and Nusse, 2012). In the presence of WNT proteins, they 
act on target cells, by binding to FZ/LRP complex at the cell surface and induce the 
connection of Axin with the phosphorylated tail of LRP. These receptors send a signal to 
numerous intracellular proteins including Dishevelled (Dvl), Axin, APC, GSK3-β and β-
catenin (Logan and Nusse, 2004). The destruction box ceases to function and newly 
synthesized β-catenin is accumulated and translocates to the nucleus. In the nucleus β-
catenin binds to Tcf/Lef DNA-binding proteins and the repressing effect of Groucho is 
inhibited. Instead β-catenin converts the Tcf/Lef complex into a transcriptional activator 
complex. Upon this binding, several transcriptional co-activators are recruited to further 
induce expression of target genes, which play a direct role in tumorigenesis (Clevers and 
Nusse, 2012; Logan and Nusse, 2004) (figure 5). Loss of function of APC caused by 
mutation stabilizes β-catenin and activates transcription of target genes. Mutation in APC 
increases the risk of colorectal and other cancers (Taipale and Beachy, 2001). Other 
mutations in the pathway can also form cancer, for example the already mentioned mutations 
activating β-catenin in medulloblastomas (Northcott et al., 2011).  
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2.1.2 Non-canonical WNT signaling  
In recent years, more and more is becoming known about the non-canonical WNT signaling 
pathways, which mediate the signals independently of β-catenin. The non-canonical WNT 
signaling can be further divided into two distinct pathways: The planar cell polarity signaling 
and the Ca2+ signaling (Komiya and Habas, 2008). 
 
Planar cell polarity signaling 
The planar cell polarity proteins create polarity within a tissue plane by asymmetric 
expression and cell morphology. Cells are organized along two axes: the PCP axis (i.e., from 
front to back) and the apical-basal axis (i.e., from top to bottom) and this is an important 
hallmark of embryonic development. Proteins involved in core PCP signaling include 
Flamingo (Celsr), Fz, Dvl, Van Gogh like 2 (Vangl2), Diego (Dgo) and Prickle. Recent 
studies have shown a surprisingly wide array of roles for PCP proteins. In the developing 
nervous system, PCP signaling is involved in many processes for example gastrulation, 
neurulation, neuronal polarity, axon guidance and tangential neuronal migration (Goodrich, 
2008; Gray et al., 2011). The canonical WNT pathway and PCP pathway have been shown to 
Figure 5. An overview of the canonical WNT signaling (Barker and Clevers, 2006). Reprinted by 
permission from Macmillan Publishers Ltd. 
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crosstalk and antagonize each other, although the mechanism is still unclear (Chan et al., 
2006). After stimulation by WNT ligands to the Fz receptor, the signal is transduced to Dvl, 
leading to activation of the small GTPases Rho and Rac (Komiya and Habas, 2008). 
Activation of Rho stimulates axon retraction and keeps the cell undifferentiated, whereas 
stimulation of Rac promotes axon extension and neuritogenesis (Katoh et al., 2000). The Rho 
subgroup consists of RhoA, RhoB and RhoC. They are involved in the actin cytoskeleton 
function and act as a molecular switch in several processes such as adhesion, migration of 
neural crest cells and cell cycle progression. They can be found in a GDP-bound inactive 
form or a GTP-bound active form. This transformation is made by specific guanine-
nucleotide exchange factors (GEFs) (Narumiya et al., 2009). The activation of GEFs is 
controlled by GTPase-activating proteins (GAPs) (Katoh et al., 2000). There are two main 
downstream effectors of Rho; one is mammalian homolog of Drosophila diaphanous (mDia) 
and the other is Rho-associated coiled-coil forming kinase (ROCK) (Narumiya et al., 2009) 
(figure 6).  
ROCKs are protein serine/threonine kinases that phosphorylate various substrates involved in 
regulating actin-myosin cytoskeleton and contractility via myosin light chain (MLC) 
phosphatase and LIM kinases. Two isoforms of ROCK exist: ROCK1 and ROCK2, sharing 
65% homology in the amino acid sequence (Riento and Ridley, 2003). ROCK1 is most 
highly expressed in lung, liver, spleen and testes, while ROCK2 is most highly expressed in 
brain and muscles (Hahmann and Schroeter, 2010). Several studies have shed light on how 
Rho proteins contribute to tumorigenesis and overexpression of ROCK has been associated 
with numerous cancers including melanoma, breast, prostate and colon cancer (Liu, 2011; 
Routhier et al., 2010; Sahai and Marshall, 2002; Zhang et al., 2014).  
The fact that embryonic development shares many similarities with cancer development and 
that these conserved pathways are deregulated in tumorigenesis, support the theory that 
certain cancers are result of development gone wrong. Accumulating evidence confirms a 
role of PCP signaling in cancer development (Wang, 2009). Molenaar et al published a paper 
in Nature 2012, identifying genes mutated in neuroblastoma tumors related to the non-
canonical WNT signaling pathway. These mutated genes are involved in growth cone 
stabilization and neurite outgrowth, important developmental signals of differentiated 
neuronal cells and neuritogenesis. Most tumors with mutations in these genes were 
aggressive high-stage neuroblastomas (Molenaar et al., 2012). In recent years, other groups 
have also reported recurrent mutations of genes involved in this signaling pathway in 
neuroblastoma (Pugh et al., 2013; Sausen et al., 2013).  
Since Rho proteins are involved in the process of tumorigenesis and seem to be important for 
cancer progression, targeting the pathway might be particularly attractive and a potential new 
target for the treatment of neuroblastoma and other types of cancer. There are several ways in 
which pharmacological agents could target this pathway: either by targeting Rho proteins or 
by targeting Rho protein effectors such as ROCK (Sahai and Marshall, 2002).  
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Ca2+ signaling 
Activation of WNT/Ca2+ pathway leads to higher levels of intracellular Ca2+ and stimulation 
of calmodulin dependent protein kinase II (CamKII) and protein kinase C (PKC) via 
phospholipase C (PLC). This is mediated via G-proteins and Dvl. In this pathway calcium 
acts as a second messenger and activates different downstream effectors (Kuhl et al., 2000; 
Wang, 2009). The pathway is important for normal development and several reports have 
shown that intracellular calcium release is essential for body plan specification and interferes 
with gastrulation (Kohn and Moon, 2005; Kuhl et al., 2000).  
 
2.2 SONIC HEDGEHOG SIGNALING  
The Hedgehog family of proteins has long been known to regulate cell growth, migration of 
cells in the neural crest and patterning during embryonal development. There are three 
identified HH subgroups: the Desert Hedgehog (Dhh), Sonic Hedgehog (Shh) and Indian 
Hedgehog (Ihh) (Echelard et al., 1993). 
HH is able to affect distal tissue, operating over a long range in a concentration dependent 
manner. In the absence of HH, the 12-span transmembrane protein Patched (Ptch) is enriched 
in primary cilia, and acts to catalytically inhibit Smoothened (Smo). Activation of the HH 
signaling is started by the binding of HH ligand to Ptch receptor that moves Ptch out of the 
cilia resulting in loss of inhibition by Ptch and activation of Smo. Smo is a seven 
transmembrane-receptor resembling the FZ family of WNT receptors. Smo is stabilized and 
activated and affects a large complex of proteins containing Cos2 (Costal-2), Fu (Fused) and 
Figure 6. Non-canonical PCP 
signaling involves interactions 
between Fz, Vang, Pk and Dgo with 
activation of RhoA and ROCK via 
Daam1, which leads to actin 
polymerisation, and Rac1 and JNK, 
which leads to microtubule 
stabilization. This regulation of 
cytoskeletal dynamics controls cell 
polarity, cell migration and convergent 
extension (Clark et al., 2012). 
Reprinted with the permission from S. 
Karger AG. 
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Sufu (Suppressor of Fused). The activation of Smo leads to triggering of the glioma-
associated oncogene (GLI) family of transcription factors, activating expression of specific 
HH target genes (Taipale and Beachy, 2001; Varjosalo and Taipale, 2008). In vertebrates, 
three forms of GLI transcription factors (GLI1-3) exist. The GLIs are zinc finger proteins that 
bind to DNA through five Zn-finger domains (Sasaki et al., 1999). It seems that GLI1 
functions as transcriptional activators of HH target genes, whereas GLI2 and GLI3 can 
function as both activators and repressors (Rahnama et al., 2006). GLIs start transcription of 
target genes including PTCH1, GLI1, GLI2, Cyclin D1, c-MYC and MYCN (Ng and Curran, 
2011; Wickstrom et al., 2013) (figure 7). 
 
 
Germline mutations in this pathway that affect HH signaling are associated with 
developmental deficits and malformations. One of the most noticeable is cyclopia associated 
with loss of SHH signaling. In this defect, the eye fields are fused in the midline causing one 
big eye (Murdoch and Copp, 2010; Taipale and Beachy, 2001). The involvement of SHH 
signaling in cancer was first discovered in nevoid basal cell carcinoma syndrome (NBCCS), 
also known as Gorlin syndrome. Gorlin syndrome is an autosomal dominant disorder linked 
to an increased risk of cancer, including medulloblastomas and basal cell carcinoma. 1-2% of 
medulloblastomas and 0.5% of basal cell carcinoma have Gorlin syndrome. In tumors, the 
mutations lock the pathway into a ligand independent state of constitutive activity (Hahn et 
al., 1996; Taipale and Beachy, 2001; Varjosalo and Taipale, 2008).  
The HH pathway is closely connected to many other signaling pathways, such as the 
canonical WNT pathway (Teglund and Toftgard, 2010). Many synthetic small molecules can 
inhibit Smo activation. There are several Smo inhibitors that entered clinical trials in both 
pediatric and adult cancers (Varjosalo and Taipale, 2008). The major drawback with these 
inhibitors is that they may be ineffective against tumors that have molecular lesions 
downstream of Smo. Therefore, attempts to develop agents that target more downstream in 
Figure 7. Sonic Hedgehog 
(SHH) acts on the 
membrane–receptor complex 
that is formed by Patched 
(PTCH) and Smoothened 
(SMO) to inhibit the 
repression of SMO by PTCH. 
SMO then signals 
intracellularly to activate 
GLI, and hence transcription 
of its target genes. (Owens 
and Watt, 2003) Reprinted by 
permission from Macmillan 
Publishers.  
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the signaling pathway have been done (Ng and Curran, 2011). In a cell-based screen one 
effective small-molecule targeted GLI was found. The molecule was named GANT61 (for 
Gli-ANTagonist) and was capable of reducing GLI-mediated transcription (Lauth et al., 
2007). Several studies show that GANT61 can reduce cancer growth and may be a novel 
treatment for cancer with aberrant activation of SHH signaling (Lauth et al., 2007; Wickstrom 
et al., 2013).  
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3 AIMS OF THE THESIS 
 
The general aim of my thesis was to investigate the possibility to develop novel therapeutic 
approaches based on biological understanding of the two most common and deadly solid 
tumors of childhood, medulloblastoma and neuroblastoma. Hopefully, this knowledge will 
lead to better survival, fewer side effects, and ultimately a better quality of life for these 
children. 
 
The specific aims of my thesis were: 
• To study the role of SHH signaling in neuroblastoma, and to investigate the effects of 
SHH inhibition on neuroblastoma growth. 
• To investigate PCP signaling in neuroblastoma cells and its effect on tumor viability. 
• To evaluate the effect of ROCK2 inhibition in neuroblastoma. 
• To gain further insight into resistance mechanisms protecting cancer cells from 
chemotherapeutic drugs. 
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4 MATERIALS AND METHODS 
The materials and methods in this thesis are here described briefly, but are also described in 
detail in papers I-IV. 
 
4.1 PATIENT MATERIAL 
All neuroblastoma tissue samples were collected at the Astrid Lindgren Hospital, Karolinska 
University Hospital. Human medulloblastoma and glioma samples were obtained from our 
cooperating partners Dr. Peter Siesjö and Dr. Anna Darabi, University of Lund whereas tissue 
samples from colon carcinoma patients were supplied by Dr. Baldur Sveinbjörnsson, 
University of Tromsö, Norway. Ethical approvals were obtained from the Karolinska 
University Hospital and Lund University Hospital. Medulloblastoma and glioma: LU1028-
03, ETIK642/2008, neuroblastoma: 2009/1369-31/1, 03–736, colon: 
http://www.biomax.us/tissue-arrays/Colon/BC05002 
 
4.2 IN VITRO 
 
Cell lines 
Human tumor cell lines from different tumor types were established from high-risk patients. 
For control purposes, the mouse neural cell line C17.2 and the MRC-5 lung fibroblast cell 
line were used. Different cell lines were used in this thesis depending on the specific purpose 
of the experiment. All cell lines were cultured in complete medium at 37°C in a humidified 
5% CO2 atmosphere. For all treatments in vitro, OptiMEM was used supplemented with 100 
µg/mL penicillin/streptomycin.  
 
Viability assay 
To measure cytotoxic effects of drugs in the different papers, the colometric formazan cell 
proliferation reagent WST-1 (Roche) was used. The method shows the metabolic activity of 
the mitochondria in the cells as a marker for vital status. In viable cells, mitochondrial 
enzymes cleave tetrazolium salt to form formazan (Guertler et al., 2011). Therefore, cell 
survival can be quantified indirectly by WST-1. Cells were plated in OptiMEM into 96-well 
plates (density 5000-10 000 cells/well) and allowed to attach overnight. The following day, 
cells were incubated with drugs in triple combinations. Absorbance at 450 nm was measured 
with a microplate reader and the survival ratios of the controls compared to treated cells were 
calculated. In the papers, cell survival is presented as survival index (SI). The IC50 value 
(inhibitory concentration 50%) was stated as the concentration giving an SI of 50%.  
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In paper I and II we used the fluorometric microculture cytotoxicity assay (FMCA), as 
described in detail previously (Lindhagen et al., 2008). Briefly, the assay is based on 
measurement of fluorescence generated from hydrolysis of fluorescein diacetate to 
fluorescein by cells with intact cell membrane. Results from FMCA have been shown to 
correlate with cell viability methods based on tetrazolium dyes (Lindhagen et al., 2008) .  
 
Immunohistochemistry/ Immunocytochemistry 
Formalin-fixed and paraffin-embedded tissue sections were processed according to the 
specific protocols (see respective paper) and used for detection and distribution of proteins in 
xenograft and human materials. Mouse embryos were fixed overnight in 4% 
paraformaldehyde in phosphate buffered saline (PBS) (pH 7.4) and cryoprotected overnight 
in 30% sucrose in PBS (see Paper III). Primary antibody was incubated 24-48 h at 4°C. 
Thereafter, sections were incubated with secondary antibody for 30 min at room temperature 
and mounted with Dapi-flouromount-G (Biotech) mounting medium. Matched isotype 
control was used as a control for non-specific staining. Pictures were taken using a Zeiss 
microscope. Quantification was performed either by counting positive stained cells or by 
measuring the stainings automatically using Leica Qwin IM500 software.  
Immunocytochemistry staining was performed on fixed cell cultures to determine the 
relationship between proteins and differentiation status in cells. Anti-β-catenin, anti-MGMT 
and mouse anti-beta-tubulin III/Tuj1 were used as primary antibodies followed by incubation 
with Alexa flour-conjugated secondary antibody and mounted with mounting medium. 
Pictures were taken on a microscope (see respective paper).  
 
Clonogenic assay 
To measure tumorigenic capacity, clonogenic assay was used. Cells were seeded in 6-well 
plates cell+ at a concentration of 150-200 cells per well, in complete medium, and allowed to 
attach before drug treatment or transfection with siRNA. After attachment, the medium was 
changed to OptiMEM containing the drug(s) of interest for 48-96 h. After 7-14 days of 
incubation in drug-free medium, cell cultures were rinsed with PBS, fixed in formaldehyde 
and stained with Giemsa (Gibco). Colonies (<75 cells/well) were counted manually. For each 
treatment, the clonogenic forming ability of treated/transfected cells compared to untreated 
controls was calculated.  
 
Western blotting 
For the analysis of proteins from tissue and cells, western blots were performed. Proteins 
were extracted from cells and tissue using RIPA buffer (25mM Tris (pH 7.8), 2mM EDTA, 
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20% glycerol, 0.1% Nonidet P-40 (NP-40), 1mM dithiothreitol) added with a MiniComplete 
protease inhibitor cocktail (Roche Diagnostic). For detection of phospho-proteins a 
phosphatase inhibitor cocktail 1 (Sigma-Aldrich) was added. Equal amounts of proteins were 
loaded into each well and separated by SDS-polyacrylamide 10% (Bio-Rad) and nylon or 
PVDF nitrocellulose membranes, probed with primary antibody (see respective paper) and 
diluted in 5% BSA or 5% dry milk in TBS-T. After washing the secondary antibody, 
conjugated with horseradish peroxidase (Cell signaling), diluted in 5% dry milk in TBS-T 
was added. Pierce super signal (Pierce, Rockford) was used for detection on Kodak films. 
ImageJ was used for pixel density analysis and relative protein expression.  
 
Measurement of cell cycle distribution 
Cells were seeded in flasks, left to attach, and treated with the drug. After treatment, cells 
were pulsed with Bromodeoxyuridine (BrdU) for 15 min, at 37°C, harvested and washed in 
PBS. Fixation of cells was performed in 4% phosphate-buffered formaldehyde (PFA), 12 
minutes at 90 °C and suspended in 95% ethanol, 4°C until analysis. Prior to FACS analysis, 
cells were stained with 40,6-diamidino-2-phenylindole (DAPI) and Anti-BrdU monoclonal, 
phycoerythrin labeled antibody (Biosite). Samples were analyzed using BD LSR II flow 
cytometry and analysis was undertaken with the FACS Diva software (BD Bioscience).  
 
Flow cytometry  
To measure sub-G0 cell population, cells were trypsinized, washed with ice-cold PBS, and 
fixed in 70% ethanol at -20°C, followed by incubation with RNase and propidium iodide 
(Sigma-Aldrich). All analyses were performed with BD LSR II Flow Cytometer and analysis 
was done with FACS Diva software (BD Biosciences). Isotype controls were used as 
negative controls.  
 
Real-time RT–PCR analyses 
Total RNA was prepared from cells with the RNeasy mini-kit (Qiagen) or TRIzol reagent 
(Life technologies) according to the manufacturer’s instructions. One hundred to 500 ng of 
total RNA was used for cDNA synthesis using a High Capacity RNA-to-cDNA kit (Applied 
Biosystems) or High capacity cDNA reverse transcription kit (Life technologies). The PCR 
experiments were performed with TaqMan primers or SYBR Green primers (see respective 
paper) and TaqMan Universal PCR Master Mix (Applied Biosystems) or Power SYBR 
Green master mix (Life technologies) in 96-well plates. The PCR reaction was performed in 
an ABI PRISM 7500 sequence detection system (Applied Biosystems) or 7300 Real-Time 
PCR system (Life technologies). All samples were performed in triplicate and all experiments 
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included a no template control. Relative expression was determined with a standard curve or 
calculated with the 2-ΔΔCt method.  
 
Luciferase assays and transfections 
Cells were plated in 24-well plates and left to attach overnight. The following day, cells were 
transfected with a TCF/LEF reporter plasmid (Super 8x TOPflash) together with a Renilla-
Luc plasmid and siRNA or cDNA (see paper II and III) (Veeman et al., 2003). Alternatively, 
cells were transfected with the TCF/LEF reporter plasmid and the Renilla-Luc, and 24 h later, 
drug treated. Super 8x TOPflash is a β-catenin reporter with TCF/LEF sites upstream of the 
luciferase reporter. It measures β-catenin mediated transcriptional activation.  
In paper I, cells were transfected with a GLI reporter plasmid 12xGLIBS-Luc together with 
Renilla-Luc and 24 h later, drug treated (Shimokawa et al., 2008). A Dual Luciferase Assay 
Kit (Promega) and a luminometer (Perkin Elmer) were used to measure luminescence. 
Renilla-Luc was used as a transfection control and the values were normalized to the Renilla-
Luc before calculating relative levels.  
All transfections were performed using Lipofectamin 2000, according to the manufacturer’s 
instructions (Invitrogen).  
 
Wound assay 
Wound assay or “in vitro scratch” assay is a method for studying cell migration in vitro. The 
method is based on the fact that cells tend to migrate and replace the lost cells into a formerly 
colonized area (Liang et al., 2007). Cells were plated into 6-well plates in serum-reduced 
medium and cultured until confluent. The cells were then transfected with siRNA or treated 
with drugs. A scratch was made using a 200µm pipette tip in the cell monolayer and images 
were captured directly and after 18 h. A line was drawn underneath the well in order to 
ensure that the identical area was photographed. Images were captured just above or below 
the line. Three independent experiments were made with at least three images per treatment. 
The results were analyzed using automated analysis in TScratch software (Geback et al., 
2009). 
  
4.3 IN VIVO 
Three animal models were used: a human xenograft model in nude mice, a transgenic mouse 
model that carries the human MYCN oncogene (TH-MYCN) and a model with transgenic 
mouse embryos. 
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Human xenografts model 
For the xenografts studies, four-six weeks immunodeficient female NMRI nu/nu mice 
(Scanbur) were used. Mice were housed and maintained under special pathogen-free 
conditions with access to sterile water and food ad libitum. Tumor cells were injected 
subcutaneously into the flank under general anesthesia (2-4% Isofluran). At the appearance of 
palpable tumors, the mice were randomized into treatment or control groups. Tumor growth 
was measured daily by using a digital caliper, and the volume was calculated by the formula 
length x width2 x 0.44. Each mouse was treated for 10-12 days and then euthanized in carbon 
dioxide. Tumors were weighed and dissected in smaller parts. The parts were either snap-
frozen in liquid nitrogen or fixed in 4% PFA. Tumor volume index (TVI) was calculated 
using the measured volume divided by the volume measured at treatment start.  
 
The TH-MYCN transgenic model 
We used the transgenic TH-MYCN mouse model that overexpresses MYCN in 
neuroectodermal cells (Weiss et al., 1997). The TH-MYCN mouse model predominantly 
develops neuroblastoma-like tumors in the abdomen, but thoracic tumors might also occur. 
The animals were obtained from the Mouse Model of Human Cancer Consortium Repository 
as a N16 backcross to the 129X1/SvJ background. The animals were housed at a maximum 
of six per cage in an enriched environment with access to food and water ad libitum. Pups 
were biopsied at two weeks of age for genotyping and further randomized. In our hands, 
100% of homozygous mice developed tumors compared to 50% of heterozygous mice 
(Carlson et al., 2013; Rasmuson et al., 2012). At four and a half weeks of age, homozygous 
mice started to receive HA-1077 treatment by intraperitoneal injections for 10 days. The 
animals were closely monitored for weight loss and signs of toxicity. At sacrifice, the animals 
were euthanized using CO2 and the tumor was excised, weighed and divided for fixation in 
4% PFA or frozen at -80°C for PCR and western blot analyses.  
 
Transgenic mouse embryos 
For paper III, transgenic mouse embryos overexpressing Vangl2, coupled to a nestin 
promotor, were generated by Karolinska Center for Transgene Technologies. In the 
production of transgenic mice, Construct was injected into 1-cell stage mouse embryos by 
pronuclear injection (Lindqvist et al., 2010). By using an appropriate plasmid/enhancer, it is 
possible to drive the expression of the gene to a specific cell population during a defined 
developmental time interval. A construct with nestin as a promotor/enhancer results in 
overexpression in neural stem cells between embryonic days (E) 7.5 and 16.5 (Johansson et 
al., 2002). Pregnant mice were sacrificed at E 8.5 or 9.5 by spinal dislocation and the 
embryos were rapidly dissected out and fixed in ice-cold 4% PFA. By PCR, transgenic 
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embryos were identified and only embryos unequivocally overexpressing the gene were 
included in the transgenic group.  
 
All animal experiments were approved by the regional ethics committee for animal research 
appointed and under the control of the Swedish Board of Agriculture and the Swedish Court 
(N304/08, N391/11, N163/03, N142/06, N391/11, N26/11). 
 
4.4 STATISTICAL ANALYSIS 
The IC50 values were determined from log concentrations-effect curves in GraphPad Prism 
(GraphPad Software) using non-linear regression analysis. For drug combination data, the 
Chou-Talalay method was used with the CalcuSyn (Biosoft) software. Analysis was 
performed as previously described and combination index (CI) at different effect levels were 
reported (Chou and Talalay, 1984; Ponthan et al., 2007). CI at 70% effect was chosen for 
presentation (IC70). Values of CI equal to 1 indicate additive, less than 0.8 indicate synergistic 
and greater than 1.2 indicate antagonistic interactions, respectively. Analysis was performed 
using one-sample t-test. 
For the in vitro and in vivo studies, parametric tests were used to determine statistically 
significant differences. Comparisons between two independent groups were analyzed by t-
test. Three or more independent groups were analyzed by two-way ANOVA followed by 
Bonferroni multiple comparison post-test. Treatment groups with repeated measurements 
over time were compared with two-way ANOVA followed by Bonferroni multiple 
comparisons post-test. Correlations were assessed with Spearman nonparametric test to 
determine if a correlation existed. Survival analysis was evaluated with log-rank test. All tests 
were two-sided, carried out in GraphPad and p<0.05 was considered significant. 
Kaplan-Meier survival estimates and gene correlation graphs were extracted from the R2 
database (R2: microarray analysis and visualization platform (http://r2.amc.nl)). 
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5 RESULTS AND DISCUSSION 
 
5.1 SHH SIGNALING IN NEUROBLASTOMA (PAPER I) 
Activation of the SHH signaling pathway results in rendered expression of a number of 
different genes important for cancer development including induced expression of MYCN 
(Teglund and Toftgard, 2010; Varjosalo and Taipale, 2008). Also both neuroblastoma cell 
lines and neuroblastoma tissue samples exhibit high expression of key molecules in the SHH 
signalling pathway (Mao et al., 2009; Schiapparelli et al., 2011). Therefore we investigated 
the effects of suppressing SHH signaling on neuroblastoma growth. Since all small molecule 
inhibitors of SHH signaling that currently are in clinical trials target SMO (Ng and Curran, 
2011; Scales and de Sauvage, 2009), we decided to investigate the effect of a compound 
specifically targeting GLI1 further downstream in the SHH signaling cascade. This was done 
to include molecular lesions located downstream of SMO. Initially we used seven human 
neuroblastoma cell lines with different biology (table 2) for evaluation of the Gli antagonist 
GANT-61 cytotoxicity compared to two Smo inhibitors: SANT1 and cyclopamine, using 
FMCA. All tested cell lines were more sensitive to GANT61, with IC50 values in the range of 
5.8-12.4 µM, compared to cyclopamine and SANT1 (figure 8). An inverse correlation was 
seen between GLI-1 and MYCN mRNA expression. High expression of GLI-1 was associated 
with increased drug sensitivity to GANT61, while cells with high expression of MYCN were 
more resistant to GANT61.  
 
 
 
 
Figure 8. IC50 (µM) for GANT 61, SANT1 and cyclopamine in seven neuroblastoma cell lines. Mean 
and S.D. are shown.  
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Cell line MYCN amp MYCN single copy Multidrug resistance 
SK-N-AS  +  
SH-SY5Y    
SK-N-FI    
SK-N-SH  + + 
SK-N-DZ +  Moderate 
IMR-32 +   
SK-N-BE (2) +  + 
Table 2. Neuroblastoma cell line characterization  
 
We also investigated the potential synergistic or additive effects of GANT-61 in combination 
with the chemotherapeutic drugs cisplatin, doxorubicin, irinotecan and vincristine that are 
commonly used in the treatment of neuroblastoma. Three neuroblastoma cell lines with 
different GANT-61 sensitivity were selected. The drug combination screening with GANT-
61 demonstrated synergistic or additive effects in all three tested cell lines. This finding is 
interesting since cancer treatment often uses a combination of different drugs, and new 
substances that synergize with existing drugs for treatment have a higher possibility to be 
included as a treatment option. One major obstacle in cancer treatment is acquired or intrinsic 
multi-drug resistance in cancer cells. One mechanism by which cancer cells acquire 
resistance to chemotherapeutic drugs is by upregulation of membrane drug proteins. The 
activated proteins eject the chemotherapeutic drugs by acting as drug efflux pumps. There are 
speculations that SHH pathway activation can be involved in resistance to chemotherapeutic 
drugs. Significant upregulation of SHH and GLI-1 expression was detected in a majority of 
remaining tumors after therapy (Sims-Mourtada et al., 2007). Furthermore, the differentiation 
status of the cell can be changed when treated with SHH in culture (Okano-Uchida et al., 
2004). Therefore, inhibiting SHH pathway may not only affect tumor proliferation, but also 
increase the effects of chemotherapy, resulting in improved cancer treatment responses.  
Since GLI-1 and GLI-2 are transcription factors, we wanted to confirm that their 
transcriptional activity was suppressed upon treatment of neuroblastoma cells with GANT-
61. This was performed with a GLI-dependent luciferase reporter plasmid (Shimokawa et al., 
2008). The transcriptional activity was suppressed by 36-80% dependent on the cell line 
investigated. In addition, a downregulation on both c-MYC and MYCN was observed on 
protein level. This was expected, since both c-MYC and MYCN are reported to be regulated 
by SHH signaling (Kenney et al., 2003; Teglund and Toftgard, 2010). GANT61 also induced 
apoptosis in all tested cell lines and reduced the number of S-phase cells.  
To see if GANT-61 activity was translatable into the in vivo situation, SK-N-AS cells were 
xenografted into the flanks of nude mice. When a tumor had been established (>0.15 ml) the 
mice were randomized to treatment or vehicle treatments by oral gavage (50 mg/kg GANT-
61) for 12 days. Tumor growth was monitored daily for 12 days. In vivo, GANT-61 
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significantly inhibited tumor growth compared to vehicle-treated mice. At day 12, tumors 
treated with GANT-61 were 63% of vehicle treated tumors (p=0.03).  
Our results highlight that neuroblastoma cells are more sensitive to GLI inhibition compared 
to SMO inhibition. Based on our findings, we can suggest that neuroblastoma cells may have 
molecular lesions located downstream of SMO and additionally, only siRNA knockdown of 
GLI had an impact on neuroblastoma cells. siRNA knockdown of SMO had no significant 
effect on neuroblastoma cell survival. Our results also demonstrate a correlation between 
GLI1 expression and sensitivity to GANT-61 and an inverse correlation between MYCN and 
GLI1. This inverse correlation was also seen when analyzing the publicly available R2 
microarray database available at (http://r2.amc.nl) (figure 9). These findings may suggest a 
shift from SHH dependent signaling to MYCN-driven signaling, causing a tumor to become 
resistant to SHH inhibition.  
In summary, the results in Paper I indicate that inhibition of SHH signaling at the level of 
GLI transcription factors is a novel treatment option to target high-risk neuroblastoma 
without MYCN amplification.  
 
 
 
  
Figure 9. A significant correlation between GLI1 and MYCN expression in neuroblastoma was 
observed in public available and validated dataset of neuroblastoma samples (Kocak dataset R=-
0.334, P=0.2x10-18, n=649). 
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5.2 TARGETING DRUG RESISTANCE IN CANCER (PAPER II)  
The development of cancer cell resistance to chemotherapeutic drugs is one of the major 
hurdles in the treatment of cancer. It has been estimated that 90% of the treatment failure 
observed in metastatic cancer is due to the development of mechanisms by the cancer cell to 
overcome the cytotoxic effects of chemotherapeutic drugs. The majority of chemotherapeutic 
drugs functions through affecting DNA replication. This strategy has been successful since 
cancer cells are rapidly proliferating and because of this have inadequate DNA repair 
mechanisms that in normal cells secure the high fidelity of DNA replication. DNA alkylators 
are a large group of cytotoxic drugs that are frequently used in cancer treatment. DNA 
alkylators induce alkylation of DNA which results in base-mispairing and DNA breakage 
during DNA replication and induction of apoptosis. To overcome the cytotoxic effects 
induced by DNA alkylators cancer cells have developed mechanisms to avoid the DNA 
damage induced by these substances. One important mechanism is to overexpress DNA 
repair enzymes such as O6-methylguanine-DNA methyltransferase (MGMT). MGMT 
efficiently removes O6-guanosine alkylation adducts in a one-step reaction that recovers the 
guanosine residue in a DNA molecule. During this reaction the double-strand DNA break is 
restored and the DNA replication functions as normal. MGMT is a so-called suicide enzyme 
in that the reaction is stoichiometric and MGMT is irreversibly inactivated by proteosomal 
degradation (Christmann et al., 2011). This makes MGMT an ideal candidate to target in 
order to restore chemosensitivity to DNA alkylators. Several drugs that inhibit the enzymatic 
function of MGMT have been developed but none of these substances has been successful in 
clinical trials mainly because of induction of toxicities in hematopoietic cells.  
In an attempt to overcome the toxicity induced by MGMT inhbition, we performed a search 
for cellular regulators of MGMT expression in tumor cells and tried to determine how to 
specifically target the regulators to lower the amount of MGMT. In paper II we show that 
activation of the canonical WNT/β-catenin signaling pathway upregulates MGMT expression 
in different cancers. Bioinformatic analysis of available expression cohorts identified a 
correlation between WNT/β-catenin signaling and MGMT expression in cancers of different 
origin. Immunofluorescence staining on human tumor tissues deriving from colon carcinoma, 
glioma, medulloblastoma and neuroblastoma revealed cellular co-localization of nuclear β-
catenin and MGMT. This correlation was also observed in the majority of investigated cell 
lines originated from these cancers. Further analyses of the 5´-flanking region of the 
hmMGMT gene for possible Tcf/Lef binding sites, detected eight possible binding sites 
within the MGMT promoter. Luciferase plasmids with MGMT-5´ regions containing 
different numbers of Tcf/Lef-binding sites were tested for their activity in cells with 
genetically or pharmacologically manipulated expression of β-catenin. An interesting finding 
was that an augmentation of luciferase activity was seen with increased number of Tcf/lef-
binding sites when cells were stimulated with LiCl or transfected with cDNA against β-
catenin whereas a repression was observed in cells transfected with siRNA against β-catenin 
or treated with the non-specific WNT signaling inhibitor, celecoxib. To further investigate if 
WNT signaling plays a role in the regulation of MGMT expression, WNT signaling was 
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genetically silenced using an inducible β-catenin shRNA. Suppression of β-catenin by 
shRNA in cells inhibited MGMT expression. These results suggest that the WNT signaling 
controls the MGMT expression.  
To analyze if WNT inhibition could potentiate the effect of the DNA-alkylating drug 
temozolomide, a panel of cell lines was treated with WNT inhibitors in combination with 
temozolomide. The inhibitors tested were the non-specific WNT signaling inhibitor 
celecoxib, the tankyrase/Axin1 inhibitors XAV-939, G007-LK, the Porcupine inhibitors Wnt-
C59, LGK974 and salinomycin, which acts by interrupting phosphorylation of the WNT co-
receptor lipoprotein receptor related protein 6 (Huang et al., 2009; Kahn, 2014; Lau et al., 
2013). Both of the tested porcupine inhibitors as well as salinomycin and celecoxib 
potentiated the cytotoxic effect of temozolomide in most of the tested cell lines (figure 10).  
 
 
 
There are several reports that show that other signaling cascades affect β-catenin expression. 
For example, several G protein-coupled receptors can activate β-catenin signaling, including 
prostaglandin E2 (PGE2) via the receptors EP2 and EP4 (Kahn, 2014). PGE2 is produced from 
arachidonic acid by a cascade of enzymes where cyclooxygenase-1 (COX-1) and 
cyclooxygenase-2 (COX-2) are rate-limiting (Smith et al., 2000). Experimental studies have 
revealed that COX-2 is involved in tumor progression (Wang and Dubois, 2010). Research 
groups have shown that inflammatory stimuli and hormones might induce COX-2 expression 
(Wang and Dubois, 2010). Based on the fact that COX-2 is overexpressed in several human 
tumors including colon carcinoma, glioma, medulloblastoma and neuroblastoma, cancer 
therapy using a combination of COX-2 inhibition and chemotherapy seems promising 
(Baryawno et al., 2008; Gasparini et al., 2003; Johnsen et al., 2004; Wang and Dubois, 2010). 
Moreover, the non-specific WNT inhibitor and COX-2 inhibitor celecoxib was the most 
Figure 10: Mean of combination index (CI) at IC70. A CI =1 denotes additive effect, CI 
significantly below 1 is defined as synergy and CI significantly above 1 as antagonism. The 
combinations with LGK974 and Wnt-C59 in T98G could not be analyzed by the median-effect 
method since the single drug effect did not achieve a full dose–response curve (as for G007-LK and 
XAV-939 in all tested cell lines).  
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effective compound inducing either synergistic or additive effect when given together with 
temozolomide in all investigated cell lines in vitro. We therefore decided to further 
investigate the effect of celecoxib. By using western blotting on protein extracts from tumor 
cells treated with celecoxib on different time points, we demonstrated a clear downregulation 
on MGMT and β-catenin expression. Moreover, cells expressing different levels of MGMT 
were treated with temozolomide alone or a combination of temozolomide and celecoxib, to 
measure clonogenic capacity. MGMT expression levels corresponded to sensitivity to 
temozolomide, and when celecoxib was used in combination, we saw a significant increase in 
sensitivity to temozolomide in cell lines with high levels of MGMT. By using the colorectal 
carcinoma cell line, LS174T, with a Tet-inducible shRNA against β-catenin, we observed a 
significant decrease in cell growth when cells with silenced β-catenin expression were treated 
with temozolomide compared to control cells. The effect was depleted when the β-catenin 
knocked cells were transfected with MGMT cDNA.  
We also tested the combination of temozolomide and inhibition of β-catenin in vivo. The 
medulloblastoma cell line D283 with low expression of MGMT and the colorectal cell line 
LS174T with high expression of MGMT were selected for the in vivo studies. Nude mice 
injected with D283 on the flank were treated with celecoxib alone, temozolomide alone or a 
combination of temozolomide and celecoxib for 12 days. We observed that the tumor growth 
inhibiting effect was significantly potentiated when celecoxib and temozolomide were 
administered together. In the β-catenin inducible cells LS174T, we saw the same effect, i.e. a 
significant inhibition of tumor growth in mice with β-catenin knocked tumors treated with 
temozolomide. The expression of MGMT was downregulated in both tumors from D283 
mice and LS174T mice. 
In summary, the results in Paper II show an indirect strategy for targeting cancer cells with 
high levels of MGMT by using inhibitors of WNT signaling. WNT inhibitors can increase the 
sensitivity of tumor cells to alkylating agents such as temozolomide, thereby increasing the 
effectiveness of the chemotherapeutic treatment. The major advantage of using indirect 
inhibition of MGMT is the avoidance of some of the toxic effects resulting from the direct 
inhibition of MGMT.  
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5.3 PLANAR CELL POLARITY SIGNALING IN NEUROBLASTOMA (PAPER III) 
It is important to understand the mechanisms that promote and regulate tumor development, 
to be able to establish future prognostic markers in neuroblastoma. As described earlier, 
neuroblastoma originates from cells in the neural crest (Brodeur, 2003; Louis and Shohet, 
2015; Ratner et al., 2016; Schulte and Eggert, 2015). Neural crest cells migrate throughout 
the body and mature into different structures. The migration is dependent on different signals 
controlling orientation and polarization (Mayor and Theveneau, 2014). In paper III we 
investigated the importance of the two PCP proteins, Prickle1 and Vangl2, in neuroblastoma 
growth. In vitro manipulation by overexpression of Prickle1 or Vangl2 suppressed cell 
viability and increased differentiation in neuroblastoma cells. Moreover, we observed a 
reduction of β-catenin activity in neuroblastoma cells. Other studies have reported that the 
canonical and planar cell polarity pathway can crosstalk and antagonize one another in cancer 
cells, which is in line with our own findings. It was also reported that high expression of 
Prickle1 inhibited β-catenin through degradation of Dvl (Chan et al., 2006). We also 
observed an upregulation of Prickle1 and a downregulation of β-catenin when neuroblastoma 
cells were treated with compounds blocking the non-canonical pathway downstream.  
Analysis of Prickle1 and Vangl2 in the open-access gene expression database R2 
(http://r2.amc.nl) confirmed that high expression of these genes in primary neuroblastoma 
patient materials is significantly associated with a better clinical prognosis and a low-risk 
disease.  
In contrast to our results in neuroblastoma cells, both the non-tumorigenic cell line C17.2 and 
transgenic mouse embryos overexpressing Vangl2 showed increased β-catenin activity and 
presented reduced differentiation. Our results highlight that expression of Prickle1 and 
Vangl2 have different modes of action in non-tumorigenic cells compared to neuroblastoma 
cells, but the role of PCP signaling in tumor development is still controversial. Given that the 
non-canonical PCP signaling antagonizes the canonical signaling, one would presume that 
PCP signaling can suppress tumor development, but some non-canonical proteins act as both 
suppressors and oncogenes dependent on tumor stage. At the early stage of cancer they act as 
suppressors and, as cancer progresses, they promote migration and invasion (Wang, 2009). It 
was recently shown that the Rictor subunit within the mammalian target of rapamycin 
complex 2 (mTORC2) binds to Prickle1 and this promotes cytoskeleton changes, cell motility 
and proliferation of breast cancer cells (Daulat et al., 2016). Also, Vangl2 is overexpressed in 
endocrine-related tumors (Hatakeyama et al., 2014) and associated with poor prognosis in 
basal breast cancer (Puvirajesinghe et al., 2016). On the other hand very low levels of 
Prickle1 and other PCP mediators were detected in pediatric but not adult adrenocortical 
tumors (Mermejo et al., 2014). Hence, more studies need to be undertaken in order to 
elucidate the importance of PCP signaling in cancer.   
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In summary, we show that the expression of Prickle1 and Vangl2 has different modes of 
action in neuroblastoma cells compared to non-tumorigenic cells and that the activity of the 
non-canonical pathway is of importance for neuroblastoma growth and prognosis.  
 
5.4 RHO-ASSOCIATED KINASE IN NEUROBLASTOMA (PAPER IV) 
Compared to adult cancer, neuroblastomas have less reported somatic mutations, with a 
median of 15 mutations. In order to get further insight into the advanced biology of 
neuroblastoma, Molenaar et al, published a paper in Nature 2012, identifying multiple 
recurrent alterations in tumors from 87 untreated neuroblastoma patients (Molenaar et al., 
2012). Among the alterations were genes involved in the non-canonical PCP WNT pathway. 
This pathway is, as previously mentioned, important for the differentiation and maturation of 
neural crest cells and the failure of neural crest cells to differentiate can result in 
neuroblastoma (Sebbagh and Borg, 2014). We therefore decided to further investigate this 
pathway and how it may be manipulated in neuroblastoma. By whole exome sequencing of 
neuroblastoma patient samples and by analyzing data from research performed by others, we 
detected frequent mutations in genes involved in neuritogenesis associated with the Rho/Rac 
signaling. Of the mutations, 58% were detected in GAP and GEF genes. As mentioned 
before, these mutations could lead to the inhibition of Rac and activation of Rho. Activated 
Rho further promotes activation of ROCK1 and ROCK2, which phosphorylate downstream 
targets important for cellular morphology (Molenaar et al., 2012; Sebbagh and Borg, 2014). 
Previous cell biological studies demonstrated that this pathway is mutated in many cancers, 
including neuroblastoma (Karlsson et al., 2009).  
The first question in this study we sought to examine was the status of Rho activity in 
neuroblastoma. We first measured the expression levels of downstream ROCK molecules 
since ROCKs are essential for proper activation of Rho signaling (O'Hayre et al., 2014). 
ROCK1 and ROCK2 were analyzed in neuroblastoma tumors and cell lines and all tested 
neuroblastoma cell lines expressed the proteins. Analysis of publically available datasets 
revealed that high levels of ROCK1 and ROCK2 were found in tumors associated with poor 
prognosis. Given that ROCK proteins are expressed in neuroblastoma, we studied the effect 
of ROCK inhibition in neuroblastoma cell lines. In Paper IV we used two ROCK inhibitors, 
HA1077 and Y27632, and one Rho inhibitor, Rhosin. The cytotoxic effects were evaluated in 
a panel of neuroblastoma cells. HA1077 demonstrated the most effective inhibition of cell 
growth and was selected for further analysis. HA1077 interacts with the ATP binding site of 
the kinase domain of ROCK1 and ROCK2 and is approved for clinical use in Japan and 
China under the name Fasudil (Feng et al., 2016). Treatment with HA1077 induced 
differentiation of neuroblastoma cells as seen by neurite outgrowth and inhibited cell 
migration. The ROCKs phosphorylate myosin light chain, which mediates cytoskeletal 
changes of importance for cell movements (Riento and Ridley, 2003). Therefore, an 
inhibition of migration was expected. Moreover, expression of MYCN after HA1077 
exposure was investigated. MYCN amplification is coupled to patient survival and 
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neuroblastoma differentiation status; therefore, drugs that inhibit the expression are highly 
warranted. Treatment of neuroblastoma cells with HA1077 resulted in increased 
phosphorylated MYCN (T58) and decreased total level of MYCN protein expression 
compared to untreated control cells. Surprisingly, no differences were found in MYCN 
mRNA levels in HA1077 treated cells compared to untreated control cells. This finding was 
unexpected, and a possible explanation for this might be that ROCK inhibits MYCN on a 
post-transcriptional level. Similar results were observed when cells were transfected with 
ROCK2 siRNA. Another interesting finding was that the SH-EP MYCN-inducible Tet21N 
neuroblastoma cell line responded differently to HA1077 treatment with and without added 
tetracyclin (Lutz et al., 1996). Following removal of tetracycline, MYCN level increased and 
cells were more sensitive to HA1077 treatment compared to tetracycline treated cells.  
To investigate the effects of HA1077 in vivo, mice with established neuroblastoma SK-N-
BE(2) xenografts were treated with HA1077 (50 mg/kg) or vehicle by daily intraperitoneal 
injections. A reduction in tumor volumes of 31% was observed in mice treated with HA1077 
compared to vehicle treated animals; the tumor growth was also significantly slower in 
HA1077 treated animals. Next we investigated the effect of HA1077 in the TH-MYCN 
transgenic model that develops MYCN driven neuroblastoma (Weiss 1997). Four and a half 
week-old homozygous mice (TH-MYCN+/+) were treated daily by intraperitoneal injections 
for nine days, and divided into two groups, 10 mg/kg and 25 mg/kg and compared to mice 
without treatment. Both treatment groups had a significantly lower tumor burden compared to 
non-treated animals and no signs of toxicity were seen during the experiment. In TH-MYCN 
mice treated with HA1077, a reduction on MYCN protein levels was observed as well as 
inhibited ROCK activity, but no change in MYCN mRNA levels.  
Treatment with HA1077 or transfection with ROCK2 siRNA resulted in decreased GSK-3β 
(Serine9) phosphorylation. GSK-3β is known to phosphorylate β-catenin in the canonical 
WNT signaling, mark it for degradation and inhibit the WNT pathway, but GSK-3β is also 
important for normal embryonic development, cell division and apoptosis (Nelson and Nusse, 
2004). Interestingly, GSK-3β can be switched on and off by other protein kinases 
phosphorylating threonine or serine residues. GSK-3β activity is suppressed by 
phosphorylation of serine 9 (Cohen and Frame, 2001). These results further support the idea 
of a post-transcriptional inhibition of MYCN by GSK-3β phosphorylation that results in 
ubiquitin mediated degradation of MYCN (summarized in figure 11). Furthermore, mutations 
in the pathway that affects the activity of ROCK may affect the expression of MYCN 
proteins in neuroblastoma patients.  
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In summary, the results in Paper IV show promising data that manipulation of the non-
canonical PCP WNT pathway through ROCK induced neuroblastoma differentiation as well 
as MYCN inhibition. 
  
Figure 11. Schematic image over the possible interactions between ROCK2 and MYCN in 
neuroblastoma. 
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6 CONCLUSIONS AND FUTURE PERSPECTIVES 
The results presented in this thesis aimed to increase our understanding of signaling pathways 
important for tumorigenesis and to identify new treatment targets in embryonal tumors. This 
could potentially lead to development of new novel therapeutic approaches that will lead to 
better survival, less side effects and ultimately better quality of life for these children.  
In Paper I we demonstrated that inhibition of SHH signaling at the level of GLI is a new 
efficient way to target neuroblastoma without MYCN amplification. This is an important 
finding since SHH signaling is deregulated in many cancers and approximately 30% of 
medulloblastoma tumors have activation of the pathway. A further study with more focus on 
targeting SHH medulloblastomas with GANT-61 would be interesting since SHH 
medulloblastomas Smo inhibitors-non responders often have mutations downstream of SMO 
or in the phosphoinositide 3-kinase (PI3K) pathway. Therefore, inhibition of SHH signaling 
at the level of GLI can be effective (Ransohoff et al., 2015). Also a combination therapy with 
SHH inhibitors plus PI3K inhibitors may represent a new promising way to target 
medulloblastomas SHH tumors. Future studies will reveal if this is a mode to avoid resistance 
to conventional chemotherapy in this group of patients.  
In Paper II we showed that a combination therapy using the WNT inhibitor celecoxib 
together with temozolomide is more effective than temozolomide given alone in cancer 
treatment in several cancer forms. Therefore this should be further evaluated in a clinical 
study as a treatment option for both pediatric brain tumors and adult cancers since therapy 
resistance is one of the biggest drawbacks in cancer therapy in general. In further research, 
the use of this mechanism could lead to development of more effective WNT inhibitors that 
can be used in combination with alkylating agents in cancer therapy.  
In Paper III and IV we provide knowledge about the non-canonical PCP pathway in 
neuroblastoma. The results of these studies propose that the pathway is important in 
tumorigenesis. The results in Paper III were mainly conducted in vitro. Therefore it is of great 
importance to go further with an in vivo experiment to investigate our findings, pointing at a 
tumor suppressive role of Prickle1 and Vangl2 in neuroblastoma. Overall, Paper III 
strengthens the idea that tumor cells and non-tumor cells have different mode of action but 
several questions remain unanswered at present. A further study with more focus on these 
differences is therefore suggested. The results in Paper IV further support the hypothesis that 
the non-canonical pathway is important to investigate in neuroblastoma. There are still many 
unanswered question about which mutations that affect tumor progression and the 
consequences and importance of the mutations. Since ROCK inhibition induces 
differentiation in a similar way as retinoic acid, a future study with more focus on 
combination therapies is therefore suggested.  
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In conclusion, there is abundant room for further progress to identify new targets in cancer 
therapy, but the findings in this thesis have provided us with new knowledge of possible 
targets that appear to be effective. I hope that the work presented in this thesis will provide us 
with new tools for the treatment of embryonal tumors.  
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